Treatment decisions in axial spondyloarthritis daily clinical practice are more than treat-to-target.

"Disclosure statement: M.v.S. received grant support for research from Eli Lily, Novartis and UCB and consulting fees/payment for presentations from AbbVie, Novartis and UCB. C.A. and L.v.M. received payment for presentations from Novartis. R.L. received consulting fees/honoraria from AbbVie, Pfizer, Novartis, Eli Lilly, UCB, Galapagos and Jansen; is chair of the EULAR Quality of Care Committee; and is the owner of Rheumatology Consultancy BV. The other authors have declared no conflicts of interest."

"Funding This work was supported by the Academic Medical Center Fellowship and a Dutch Organization for Health Research and Development VIDI grant (91718371) to L.v.B. Disclosurestatement: M.v.S. received grant support for research from Eli Lily, Novartis and UCB and consulting fees/payment for presentations from AbbVie, Novartis and UCB. C.A. and L.v.M. received payment for presentations from Novartis. R.L. received consulting fees/honoraria from AbbVie, Pfizer, Novartis, Eli Lilly, UCB, Galapagos and Jansen; is chair of the EULAR Quality of Care Committee; and is the owner of Rheumatology Consultancy BV. The other authors have declared no conflicts of interest."